Alkem laboratories posts strong Q2 revenue and profit growth

Alkem Laboratories reported a consolidated total revenue from operations of ₹40,010 Mn for Q2 FY26, marking a 17.2% year-over-year increase. Consolidated profit before tax (after exceptional items) reached ₹8,958 Mn, up 14.8% year-over-year, while net profit (after minority interest) rose 11.1% to ₹7,651 Mn. The company's EBITDA for the quarter stood at ₹9,208 Mn, a 22.3% increase from the previous year, with an EBITDA margin of 23.0%.

Domestic sales grew by 12.4% year-over-year to ₹27,660 Mn, contributing 69.9% to total sales. International sales surged by 29.5% year-over-year to ₹11,890 Mn, with US sales increasing 28.0% to ₹7,649 Mn. For the six months ended September 30, 2025, consolidated revenue from operations was ₹73,721 Mn, a 14.4% increase, and net profit (after minority interest) was ₹14,293 Mn, up 15.8%.

The company also highlighted its R&D expenditure for Q2 FY26 at ₹1,302 Mn, representing 3.3% of total revenue from operations. Alkem filed two ANDAs, received one tentative ANDA approval, and launched four products in the US market during the quarter.